CompletedNCT01281527
Flexible-Dose Paliperidone Injections for Schizophrenia
About this title
Read the official source — NCT01281527Researchers studied Paliperidone Palmitate to find out how it affected psychotic symptoms in people with schizophrenia.
Medication studyAges 18+Multiple countries
Understand this study
What did researchers investigate?
Researchers studied Paliperidone Palmitate to find out how it affected psychotic symptoms in people with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria applied.
- Listed locations
- Salzburg and 126 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateNovember 2010
- Recruitment status
- Completed
- Enrollment listed in the registry
- 1,044
- Sponsor
- Janssen-Cilag International NV
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- France, United Kingdom, Switzerland, ...
- Age range
- Over 18 Years
- Official registry ID
- NCT01281527
- Official title
Show the full official title
A 6-month, Open Label, Prospective, Multicenter, International, Exploratory Study of a Transition to Flexibly Dosed Paliperidone Palmitate in Patients With Schizophrenia Previously Unsuccessfully Treated With Oral or Long-acting Injectable Antipsychotics
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Salzburg, Austria · Brussels, Belgium · Dave, Belgium
125 more locations
- Diest, Belgium
- Kruishoutem, Belgium
- Liège, Belgium
- Melle, Belgium
- Roeselare, Belgium
- Sint-Denijs-Westrem, Belgium
- Tournai, Belgium
- Rijeka, Croatia
- Zagreb, Croatia
- Aalborg, Denmark
- København V, Denmark
- Randers, Denmark
- Tallinn, Estonia
- Bar-le-Duc, France
- Bron, France
- Clermont-Ferrand, France
- Dax, France
- Dijon, France
- Dole, France
- Lille, France
- Limoges, France
- Montpellier, France
- Nîmes, France
- Paris, France
- Saint-Nazaire, France
- Saint-Priest-en-Jarez, France
- Strasbourg, France
- Villejuif, France
- Bad Saarow, Germany
- Berlin, Germany
- Bielefeld, Germany
- Bochum, Germany
- Butzbach, Germany
- Dresden, Germany
- Gelsenkirchen, Germany
- Greifswald, Germany
- Hamburg, Germany
- Heidelberg, Germany
- Königsbrück, Germany
- Mittweida, Germany
- Oranienburg, Germany
- Regensburg, Germany
- Stralsund, Germany
- Ulm, Germany
- Westerstede, Germany
- Würzburg, Germany
- Arta, Greece
- Athens, Greece
- Katerini, Greece
- Thessaloniki, Greece
- Thessalonikis, Greece
- Budapest, Hungary
- Debrecen, Hungary
- Pécs, Hungary
- Pardesiyya, Israel
- Ramat Gan, Israel
- Tirat Hacarmel, Israel
- Daugavpils, Latvia
- Jelgava, Latvia
- Liepāja, Latvia
- Riga, Latvia
- Sigulda, Latvia
- Strenči, Latvia
- Panevezys, Lithuania
- Vilnius, Lithuania
- Groningen, Netherlands
- Almada, Portugal
- Angra do Heroísmo, Portugal
- Castelo Viegas, Portugal
- Coimbra, Portugal
- Lisbon, Portugal
- Porto, Portugal
- Alcorcón, Spain
- Alicante, Spain
- Barcelona, Spain
- Burgos, Spain
- Coslada, Spain
- Elche, Spain
- Madrid, Spain
- Málaga, Spain
- Palma de Mallorca, Spain
- Sant Boi de Llobregat, Spain
- Sant Joan d'Alacant, Spain
- Santa Coloma de Gramenet, Spain
- Vigo, Spain
- Zamora, Spain
- Zaragoza, Spain
- Gothenburg, Sweden
- Lidingö, Sweden
- Malmö, Sweden
- Mölndal, Sweden
- Spånga, Sweden
- Upplands Vasby, Sweden
- Solothurn, Switzerland
- Zurich, Switzerland
- Ankara, Türkiye
- Diyarbakır, Türkiye
- Gaziantep, Türkiye
- Istanbul, Türkiye
- Izmir, Türkiye
- Trabzon, Türkiye
- Dnipro, Ukraine
- Donetsk, Ukraine
- Hlevakha, Ukraine
- Ivano-Frankivsk, Ukraine
- Kharkiv, Ukraine
- Kiev, Ukraine
- Lviv, Ukraine
- Odesa, Ukraine
- Poltava, Ukraine
- Simferopol, Ukraine
- Smila, Ukraine
- Ternopil, Ukraine
- Uzhhorod, Ukraine
- Yevpatoriya, Ukraine
- Barnet, United Kingdom
- Birmingham, United Kingdom
- Cambridge, United Kingdom
- Coventry, United Kingdom
- Darlington, United Kingdom
- Lincoln, United Kingdom
- London, United Kingdom
- Prescott, United Kingdom
- Stoke-on-Trent, United Kingdom
- Türkiye
Interested in joining this study?
Questions about this study
What did researchers investigate?
Researchers studied Paliperidone Palmitate to find out how it affected psychotic symptoms in people with schizophrenia.
Who is behind this study?
The study sponsor is Janssen-Cilag International NV.
Did this study involve medication?
Yes. The study involved medication, including Paliperidone Palmitate.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
A 12-week, Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia
A 24-month, Prospective, Randomized, Active-Controlled, Open-Label, Rater Blinded, Multicenter, International Study of the Prevention of Relapse Comparing Long-Acting Injectable Paliperidone Palmit...